Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases 

Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor, Meropenem-Pilabactam (formerly Meropenem-ANT3310) at the 36th Congress of the European Society of Clinical Microbiology and Infectious Diseases 

Labège, France, April 27, 2026 — Antabio, a clinical-stage biopharmaceutical company developing novel antibacterial treatments targeting drug-resistant infections identified by WHO and CDC as critical priorities, today highlighted the presentation of new data on...
ANTABIO Raises €25 million in Series B Financing

ANTABIO Raises €25 million in Series B Financing

Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion of Phase 2 trials. Labège, France, 12 December 2023. Antabio SAS, a...